TNXP
Tonix Pharmaceuticals Holding Corp.
NASDAQ · Healthcare · Biotechnology · US
$5.73
−5.13%Year over year
Reported trailing growth
- Revenue
- +196.0%
- EBITDA
- -95.0%
- EBIT
- —
- EPS
- +20.7%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- +231.5%
- EBITDA
- +19.7%
- EPS
- +40.1%
Three-year CAGR
- Revenue
- +29.9%
- EBITDA
- -64.2%
- EBIT
- +8.0%
- Net income
- +4.6%
- EPS
- +91.7%
- Free cash flow
- -69.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026